National Cancer Institute (NCI): Thyroid Carcinoma, Anaplastic trials
The registry lists 11 Thyroid Carcinoma, Anaplastic studies with National Cancer Institute (NCI) as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 1 3Phase 2 8No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid CancerTerminatedNCT03002623Phase 2Results posted
- A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)CompletedNCT01240590Phase 1/2Results posted
- Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid CancerCompletedNCT01236547Phase 2Results posted
- Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid CancerCompletedNCT00625846Phase 2Results posted
- Sorafenib in Treating Patients With Advanced Anaplastic Thyroid CancerTerminatedNCT00126568Phase 2Results posted
- Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid CancerCompletedNCT00095693Phase 2
- Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
- Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid TumorsCompletedNCT00019331Phase 2
- Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerCompletedNCT00005842Phase 1
- Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid CancerCompletedNCT00004089Phase 2
- Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1